Human IgE responses to Schistosoma mansoni and resistance to reinfection.
Schistosoma mansoni infected Kenyan patients were treated and the intensities of their reinfections were followed over the next two years. In addition, their pre- and six month post-treatment serum levels of IgG1-4, IgM, and IgE, specific for schistosomula, egg and adult worm, were measured in ELISA. No reinfection took place before six months post-treatment. Reinfection intensities varied with age; the younger children becoming reinfected at significantly higher intensities than older individuals. When antibody and reinfection levels were compared, only the six month post-treatment IgE response against adult worm correlated negatively with intensities of reinfection and, therefore, was predictive of resistance or immunity to reinfection. IgE and IgG specific Western Blots were carried out. The adult worm antigens recognized by IgE were restricted compared with the IgG responses of the same patients, although no individual antigen was uniquely recognized by the IgE isotype. A dominant 22 kDa antigen was recognized by most but not all high IgE responders. Patients with IgE responses against this antigen suffered significantly lower subsequent levels of reinfection, compared with non-responders. A monospecific rabbit antiserum against the 22 kDa adult worm antigen showed that this antigen is specifically located in the tegument of the adult worm and of 'lung' and 'liver' stage schistosomula, but is absent from the early 'skin' schistosomula. It is possible that this antigen is a target for human IgE mediated immune effector mechanisms active against the post skin stage schistosomula and that this is boosted by the death of adult worms.
Dunne
D W
DW
Department of Pathology, University of Cambridge, UK.
Butterworth
A E
AE
Fulford
A J
AJ
Ouma
J H
JH
Sturrock
R F
RF
D000328:Adult; D000367:Age Factors; D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity; D000947:Antigens, Helminth / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D015801:Helminth Proteins / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D007073:Immunoglobulin E / Q000096:biosynthesis / Q000276:immunology*; D007630:Kenya / Q000453:epidemiology; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology; D009928:Organ Specificity; D012008:Recurrence; D012550:Schistosoma mansoni / Q000254:growth & development / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D000954:Antigens, Surface; D015801:Helminth Proteins; D008562:Membrane Glycoproteins; C072491:membrane glycoprotein antigen GP22, Schistosoma; D007073:Immunoglobulin E